Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.24, $0.12 better than the analyst estimate of $1.12. Revenue for the quarter came in at $412 million versus the consensus estimate of $408.87 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.